US2013071924A1PendingUtilityA1

Cells exhibiting neuronal progenitor cell characteristics and methods of making them

59
Assignee: SANBIO INCPriority: Apr 12, 2004Filed: Nov 8, 2012Published: Mar 21, 2013
Est. expiryApr 12, 2024(expired)· nominal 20-yr term from priority
Inventors:Mari Dezawa
A61P 25/00A61P 25/02A61K 35/12C12N 2501/70C12N 5/0619C12N 2506/1353C12N 2501/13C12N 2501/415C12N 2501/155C12N 2501/01C12N 2501/115C12N 2501/727C12N 2501/60A61K 35/28C12N 5/0602C12N 5/06
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed are cells exhibiting neuronal progenitor cell characteristics, and methods of making them from marrow adherent stem cells by regulating cellular pathways in the marrow adherent stem cells that are associated with glial transdifferentiation of the marrow adherent stem cells.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method for transdifferentiating marrow adherent stem cells (MASCs the method comprising incubating the MASCs with a glial regulating agent, wherein the glial regulating agent is a JAK/STAT inhibitor. 
     
     
         2 . The method of  claim 1 , wherein the MASCs are selected from the group consisting of human marrow adherent stem cells, rat marrow adherent stem cells, mouse marrow adherent stem cells, primate marrow adherent stem cells, pig marrow adherent stem cells, cow marrow adherent stem cells, and sheep marrow adherent stem cells. 
     
     
         3 . The method of  claim 2 , wherein the MASCs are human MASCs. 
     
     
         4 . The method of  claim 1 , wherein the JAK/STAT inhibitor is an inhibitor of STAT1 or STAT3. 
     
     
         5 . The method of  claim 1 , wherein the JAK/STAT inhibitor is a polypeptide. 
     
     
         6 . The method of  claim 5 , wherein the incubation comprises transfection of the MASCs with a polynucleotide encoding the JAK/STAT inhibitor. 
     
     
         7 . The method of  claim 1 , wherein the JAK/STAT inhibitor is 4-(4′-hydroxyphenyl)amino-6,7-dimethoxyquinazoline. 
     
     
         8 . The method of  claim 1 , wherein the JAK/STAT inhibitor is a RNAi molecule. 
     
     
         9 . The method of  claim 1 , wherein the JAK/STAT inhibitor is an antisense oligonucleotide. 
     
     
         10 . A method for inhibiting transdifferentiation of MASCs into glial cells, the method comprising incubating the MASCs with a glial regulating agent, wherein the glial regulating agent is a JAK/STAT inhibitor. 
     
     
         11 . The method of  claim 10 , wherein the MASCs are selected from the group consisting of human marrow adherent stem cells, rat marrow adherent stem cells, mouse marrow adherent stem cells, primate marrow adherent stem cells, pig marrow adherent stem cells, cow marrow adherent stem cells, and sheep marrow adherent stem cells. 
     
     
         12 . The method of  claim 11 , wherein the MASCs are human MASCs. 
     
     
         13 . The method of  claim 10 , wherein the JAK/STAT inhibitor is an inhibitor of STAT1 or STAT3. 
     
     
         14 . The method of  claim 10 , wherein the JAK/STAT inhibitor is a polypeptide. 
     
     
         15 . The method of  claim 14 , wherein the incubation comprises transfection of the MASCs with a polynucleotide encoding the JAK/STAT inhibitor. 
     
     
         16 . The method of  claim 10 , wherein the JAK/STAT inhibitor is 4-(4′-hydroxyphenyl)amino-6,7-dimethoxyquinazoline. 
     
     
         17 . The method of  claim 10 , wherein the JAK/STAT inhibitor is a RNAi molecule. 
     
     
         18 . The method of  claim 10 , wherein the JAK/STAT inhibitor is an antisense oligonucleotide. 
     
     
         19 . A composition comprising:
 (a) marrow adherent stem cells (MASCs), and   (b) a JAK/STAT inhibitor.   
     
     
         20 . The composition of  claim 19 , wherein the MASCs are selected from the group consisting of human marrow adherent stem cells, rat marrow adherent stem cells, mouse marrow adherent stem cells, primate marrow adherent stem cells, pig marrow adherent stem cells, cow marrow adherent stem cells, and sheep marrow adherent stem cells. 
     
     
         21 . The composition of  claim 20 , wherein the MASCs are human MASCs. 
     
     
         22 . The composition of  claim 19 , wherein the JAK/STAT inhibitor is an inhibitor of STAT1 or STAT3. 
     
     
         23 . The composition of  claim 19 , wherein the JAK/STAT inhibitor is a polypeptide. 
     
     
         24 . The composition of  claim 19 , wherein the JAK/STAT inhibitor is a polynucleotide encoding a polypeptide JAK/STAT inhibitor. 
     
     
         25 . The composition of  claim 19 , wherein the JAK/STAT inhibitor is 4-(4′-hydroxyphenyl)amino-6,7-dimethoxyquinazoline. 
     
     
         26 . The composition of  claim 19 , wherein the JAK/STAT inhibitor is a RNAi molecule. 
     
     
         27 . The composition of  claim 19 , wherein the JAK/STAT inhibitor is an antisense oligonucleotide.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.